Literature DB >> 6699669

Prognostic factors influencing survival of patients with advanced colorectal cancer: hepatic-artery infusion versus systemic intravenous chemotherapy for liver metastases.

A Y Bedikian, T T Chen, M A Malahy, Y Z Patt, G P Bodey.   

Abstract

In this study of 232 patients with histologically confirmed large bowel carcinoma, patient- and tumor-related characteristics were examined and their effect on prognosis was determined. Serum alkaline phosphatase and albumin concentrations, symptom duration prior to diagnosis of the primary tumor, and the status of the primary tumor showed the strongest relationship to survival after diagnosis of surgically noncurable disease. Patients who had normal serum alkaline phosphatase and albumin concentrations, patients whose symptoms lasted over 12 months before diagnosis, and patients whose primary tumor had been resected before diagnosis of noncurable disease had a good prognosis. Performance status, weight loss, sex, presence of liver metastasis, hemoglobin concentration, and absolute lymphocyte or monocyte counts in the peripheral blood, at time of diagnosis of surgically noncurable disease, were significant factors when examined individually. One hundred seventy-nine patients with metastatic colorectal cancer confined to the liver were selected from 601 patients who received chemotherapy for advanced colorectal cancer over 10-year periods to compare the efficacy of hepatic-artery infusion therapy with that of intravenous 5-fluoropyrimidine--containing chemotherapy. The two groups were similar with respect to prognostic factors. The hepatic-artery infusion chemotherapy produced a higher response rate than intravenous chemotherapy, but did not result in significant prolongation of survival.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699669     DOI: 10.1200/JCO.1984.2.3.174

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  8 in total

1.  The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma.

Authors:  H Mellstedt; J E Frödin; P Ragnhammar; G Masucci; J Shetye; B Christensson; P Biberfeld; J Makower; P Pihlstedt; B Cedermark
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  Immunohistochemical monitoring of metastatic colorectal carcinoma in patients treated with monoclonal antibodies (MAb 17-1A).

Authors:  J Shetye; J E Frödin; B Christensson; C Grant; B Jacobsson; S Sundelius; M Sylvén; P Biberfeld; H Mellstedt
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

3.  Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy.

Authors:  Miaozhen Qiu; Yi-xin Zhou; Yin Jin; Zi-xian Wang; Xiao-li Wei; Hong-yu Han; Wen-feng Ye; Zhi-wei Zhou; Dong-sheng Zhang; Feng-hua Wang; Yu-hong Li; Da-jun Yang; Rui-hua Xu
Journal:  Support Care Cancer       Date:  2014-12-11       Impact factor: 3.603

4.  Relationship between systemic 5-FU passage and response in colorectal cancer patients treated with intrahepatic chemotherapy.

Authors:  G Milano; M Namer; J L Boublil; R Khater; M Frenay; A Thyss; J Bourry; C Philip; N Renée; J N Bruneton
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  The vascularization of liver metastases. Histological investigation of gelatine-injected liver specimens with special regard to the vascularization of micrometastases.

Authors:  G Haugeberg; T Strohmeyer; W Lierse; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases.

Authors:  N C Tebbutt; A R Norman; D Cunningham; M E Hill; D Tait; J Oates; S Livingston; J Andreyev
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

7.  Update in cancer chemotherapy: gastrointestinal cancer--colorectal cancer, Part 1.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1986-04       Impact factor: 1.798

Review 8.  Transcatheter therapy for malignant neoplasms.

Authors:  D M Coldwell; J E Mortimer
Journal:  West J Med       Date:  1989-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.